NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Have you read the PR news about the trial of colorectal cancer by Merck in collaboration with NWBO? Did you watch the presentation by Dr. Liau? According to Dr. Liau, the intense anti-tumor response as shown in the figure which happened to the fifth enrolled patient was observed also in several others. I don't think colorectal cancer has immune privilege issue or other special issues like brain. If the same combination in the combo trial was adopted in the colorectal cancer trial, without doubt the same magnitude of anti-tumor intensity would happen to colorectal caner patient. Assuming Merck observed the same level of anti-tumor response in colorectal cancer patient, I have no doubt Merck would take whatever price to replace BMS in the combo trial on rGBM as one of the collaborators. This may not be the facts. it is amusing to think this way. But definitely not amusing for those on the other side of the fence.

After completing certain preparatory activities, including obtaining regulatory approvals, the Phase II trial will treat patients for up to 6 months with DCVax®-L and the checkpoint inhibitor Pembrolizumab, followed by long-term follow-up. The effects of this combination therapy will be monitored with magnetic resonance imaging (MRI) as well as “liquid biopsy” measures.

The trial will be conducted at about 10 sites in Germany, and UMC Mainz, Germany, will be the Sponsor. The study may also be expanded to other countries. MSD Sharp & Dohme GmbH supports the study by providing their novel checkpoint inhibitor Pembrolizumab. Close cooperation exists with Cognate BioServices and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig, Germany.